A 40-year-old man with class 2 obesity (body mass index 39.8 kg/m2) and insulin resistance (HOMA-IR 5.0) initially responded minimally to tirzepatide, achieving less than 5% weight loss despite escalating the weekly dose to 15 mg. The patient’s insulin resistance was characterized by a high HOMA-IR value.
Clinical Response and Receptor Activity
Following a switch to semaglutide at 2.4 mg weekly, the patient experienced a 20% weight loss over six months. This transition was accompanied by normalization of fasting glucose levels and a significant improvement in appetite control. Analysis suggests that adipose tissue GIP receptor downregulation, potentially linked to class 2 obesity and insulin resistance, may contribute to differing responses to dual GIP/GLP-1 receptor agonists. The study highlights the potential for intact central GLP-1 receptor signaling to influence treatment outcomes.
Key Considerations in Obesity Pharmacotherapy
The case emphasizes the importance of considering individual patient characteristics, such as insulin resistance, when selecting obesity pharmacotherapy. Key learning points include the association of markedly elevated baseline insulin resistance (HOMA-IR ≥4-5) with a potential poor response to tirzepatide. Persistent hyperphagia during tirzepatide treatment serves as an early indicator of non-response. Furthermore, a nonresponse to tirzepatide does not necessarily preclude a response to semaglutide.